<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02261389</url>
  </required_header>
  <id_info>
    <org_study_id>KRONOS</org_study_id>
    <secondary_id>PONS-S Italy</secondary_id>
    <nct_id>NCT02261389</nct_id>
  </id_info>
  <brief_title>Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET</brief_title>
  <official_title>Three-monthly Dynamic Evaluation of CEA and CA 15.3 vs Usual Practice in the Follow-up of Early Breast Cancer Patients: a Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PONS-S, Augsburg, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda ULSS3, Centro Regionale Biomarcatori, Regione Veneto, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of follow-up in asymptomatic breast cancer patients during and after
      adjuvant treatment is to detect breast cancer recurrence and metastatic disease.The aim of
      this trial is to verify if, in asymptomatic patients, the serial measurement of serum CEA and
      CA 15.3, with diagnostic imaging procedures (18FDG-PET) performed only in case of a critical
      increase of serum CEA and CA 15.3 level, can anticipate the diagnosis of breast cancer local
      and distant recurrence compared to the usual follow-up practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time interval between date of randomization and date of diagnosis of disease distant recurrence</measure>
    <time_frame>Participants will be followed from date of randomization until the date of first documented disease distant recurrence or date of death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Primary objective of the study is to verify if the experimental arm (serial measurement of serum CEA and CA 15.3 with diagnostic imaging procedures - i.e. 18FDG-PET- performed only in case of critical increase of serum markers level) can anticipate the diagnosis of breast cancer loco-regional (except for in-breast recurrence) or distant metastases compared to the control arm (usual follow-up practice).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predefined critical difference of CEA and CA15-3</measure>
    <time_frame>Participants will be followed from date of randomization until the date of first documented disease distant recurrence or date of death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Secondary objective is to evaluate the Positive Predictive Value (PPV) and the Negative Predictive Value (NPV) of CEA and CA15.3 dynamic changes in the diagnosis of breast cancer loco-regional (except for in-breast recurrence) or distant metastases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory analysis in the different subtypes</measure>
    <time_frame>Participants will be followed from date of randomization until the date of first documented disease distant recurrence or date of death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Secondary objective is to perform an exploratory analysis on diagnostic anticipation in the different subtypes (ER and HER2 status)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging diagnostic tests evaluation</measure>
    <time_frame>Participants will be followed from date of randomization until the date of first documented disease distant recurrence or date of death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Secondary objective is to measure how many imaging diagnostic tests will be avoided in the experimental arm compared to the control arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient quality of life evaluation</measure>
    <time_frame>Participants will be followed from date of randomization until the date of first documented disease distant recurrence or date of death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Secondary objective is to compare the quality of life in the two arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A, usual follow-up practice</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Imaging studies and serum markers (CEA, CA 15.3, others) performed according to local practice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B, tumor markers assessment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serum CEA and CA 15.3 performed every 3 months. No imaging studies allowed in asymptomatic patients: imaging studies (18 FDG-PET) performed only in case of critical increase of CEA and /or CA 15.3 serum levels (+100% for CEA and +75% for CA15.3), even if in the normal range.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Arm B, tumor markers assessment</intervention_name>
    <description>Tumor markers assessment every three months through the study or until disease recurrence</description>
    <arm_group_label>Arm B, tumor markers assessment</arm_group_label>
    <other_name>CEA</other_name>
    <other_name>CA15-3</other_name>
    <other_name>18FDG-PET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥18 years.

          -  Histologically confirmed stage I-III epithelial breast cancer.

          -  Adequate surgery of breast and axilla:

               1. patients must have undergone either a total mastectomy or breast conserving
                  surgery

               2. surgical margins of the resected specimen must be histologically free of invasive
                  tumor.

          -  Cohort 1: if chemotherapy and/or radiotherapy are indicated the patients must be
             randomized between 1 month and 2 months from the end of chemotherapy and/or
             radiotherapy; if only hormonal adjuvant therapy is indicated the patients must be
             randomized within 3 months from the completion of surgery

          -  Cohort 2: patients must be randomized in the trial after 5 years of follow-up without
             relapse (but within year 6)

          -  Signed informed consent obtained prior to any study-specific procedures.

        Exclusion Criteria:

          -  Histologically confirmed stage 0 epithelial breast cancer (carcinoma in situ).

          -  Special histologies with a high or low risk of relapse (i.e. sarcoma and tubular
             carcinoma)

          -  T1a and T1b tumors with all the following characteristics: G1-2 and N0 and RE &gt; 10%,
             RPg &gt; 10% and HER2 negative and Ki67≤14%

          -  Evidence of distant metastases

          -  Patients participating to other clinical trials requiring follow-up not equal to
             standard

          -  Previous history of cancer within 5 years from randomization (except for appropriately
             treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, stage I uterine
             cancer, or other non-breast malignancies with an outcome similar to those mentioned
             above)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Zamagni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria di Bologna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudio Zamagni, MD</last_name>
    <phone>051 2144548</phone>
    <phone_ext>+39</phone_ext>
    <email>zamagniclaudio.sper@aosp.bo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Sanitaria dell'Alto Adige - Ospedale di Bressanone</name>
      <address>
        <city>Bressanone</city>
        <state>Bolzano</state>
        <zip>39042</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Verena Thalmann, MD</last_name>
      <email>verena.thalmann@sabes.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria dell'Alto Adige - Ospedale di Merano</name>
      <address>
        <city>Merano</city>
        <state>Bolzano</state>
        <zip>39012</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert Heidegger</last_name>
      <email>herbert.heidegger@asbmeran-o.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASL13 - Presidio Ospedaliero Mirano, U.O.C. Oncologia ed Ematologia Oncologica</name>
      <address>
        <city>Mirano</city>
        <state>Venezia</state>
        <zip>30035</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donata Sartori</last_name>
      <email>ds1961@iol.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Zamagni, MD</last_name>
      <phone>051 2144548</phone>
      <phone_ext>+39</phone_ext>
      <email>zamagniclaudio.sper@aosp.bo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria dell'Alto Adige - Ospedale Centrale di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Cretella, MD</last_name>
      <email>elisabetta.cretella@sabes.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Frassoldati</last_name>
      <email>a.frassoldati@ospfe.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera S. Maria Nuova di Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giancarlo Bisagni</last_name>
      <email>Giancarlo.Bisagni@asmn.re.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>Claudio Zamagni MD</investigator_full_name>
    <investigator_title>MD Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>follow-up</keyword>
  <keyword>tumor markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

